The role of nonsense-mediated decay in neuronal ceroid lipofuscinosis

被引:40
作者
Miller, Jake N. [1 ,2 ]
Chan, Chun-Hung [1 ]
Pearce, David A. [1 ,2 ]
机构
[1] Sanford Res USD, Sanford Childrens Hlth Res Ctr, Sioux Falls, SD 57104 USA
[2] Univ S Dakota, Sanford Sch Med, Dept Pediat, Sioux Falls, SD 57104 USA
关键词
MESSENGER-RNA DECAY; PROTEIN THIOESTERASE DEFICIENCY; TRIPEPTIDYL-PEPTIDASE-I; READ-THROUGH; TRANSLATIONAL REPRESSION; POSTNATAL DIAGNOSIS; MOLECULAR-GENETICS; MUTATIONS; INFANTILE; ASSAY;
D O I
10.1093/hmg/ddt120
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neuronal ceroid lipofuscinosis (NCL), commonly referred to as Batten disease, is a group of autosomal recessive neurodegenerative diseases of childhood characterized by seizures, blindness, motor and cognitive decline and premature death. Currently, there are over 400 known mutations in 14 different genes, leading to five overlapping clinical variants of NCL. A large portion of these mutations lead to premature stop codons (PTCs) and are predicted to predispose mRNA transcripts to nonsense-mediated decay (NMD). Nonsense-mediated decay is associated with a number of other genetic diseases and is an important regulator of disease pathogenesis. We contend that NMD targets PTCs in NCL gene transcripts for degradation. A number of PTC mutations in CLN1, CLN2 and CLN3 lead to a significant decrease in mRNA transcripts and a corresponding decrease in protein levels and function in patient-derived lymphoblast cell lines. Inhibiting NMD leads to an increased transcript level, and where protein function is known, increased activity. Treatment with read-through drugs also leads to increased protein function. Thus, NMD provides a promising therapeutic target that would allow read-through of transcripts to enhance protein function and possibly ameliorate Batten disease pathogenesis.
引用
收藏
页码:2723 / 2734
页数:12
相关论文
共 54 条
[21]   NMD: a multifaceted response to premature translational termination [J].
Kervestin, Stephanie ;
Jacobson, Allan .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2012, 13 (11) :700-712
[22]  
Kohan R, 2011, CURR PHARM BIOTECHNO, V12, P867, DOI 1389-2010/11 $58.00+.00
[23]   Update of the Mutation Spectrum and Clinical Correlations of over 360 Mutations in Eight Genes that Underlie the Neuronal Ceroid Lipofuscinoses [J].
Kousi, Maria ;
Lehesjoki, Anna-Elina ;
Mole, Sara E. .
HUMAN MUTATION, 2012, 33 (01) :42-63
[24]   Pharmaceutical therapies to recode nonsense mutations in inherited diseases [J].
Lee, Hui-Ling Rose ;
Dougherty, Joseph P. .
PHARMACOLOGY & THERAPEUTICS, 2012, 136 (02) :227-266
[25]   Nonsense-mediated translational repression involves exon junction complex downstream of premature translation termination codon [J].
Lee, Hyung Chul ;
Oh, Nara ;
Cho, Hana ;
Choe, Junho ;
Kim, Yoon Ki .
FEBS LETTERS, 2010, 584 (04) :795-800
[26]   Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans [J].
Lewis, BP ;
Green, RE ;
Brenner, SE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (01) :189-192
[27]   Mutations in the palmitoyl-protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits [J].
Mitchison, HM ;
Hofmann, SL ;
Becerra, CHR ;
Munroe, PB ;
Lake, BD ;
Crow, YJ ;
Stephenson, JBP ;
Williams, RE ;
Hofman, IL ;
Taschner, PEM ;
Martin, JJ ;
Philippart, M ;
Andermann, E ;
Andermann, F ;
Mole, SE ;
Gardiner, RM ;
O'Rawe, AM .
HUMAN MOLECULAR GENETICS, 1998, 7 (02) :291-297
[28]  
Mole S E, 2001, Eur J Paediatr Neurol, V5 Suppl A, P7, DOI 10.1053/ejpn.2000.0427
[29]   Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses [J].
Mole, SE ;
Williams, RE ;
Goebel, HH .
NEUROGENETICS, 2005, 6 (03) :107-126
[30]   The genetic spectrum of human neuronal ceroid-lipofuscinoses [J].
Mole, SE .
BRAIN PATHOLOGY, 2004, 14 (01) :70-76